NasdaqGS - Nasdaq Real Time Price USD

Unity Biotechnology, Inc. (UBX)

Compare

2.2400

-0.0100

(-0.44%)

At close: January 29 at 4:00:01 PM EST

2.2500

+0.01

+(0.45%)

After hours: 7:17:23 PM EST

UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors (the “Board”) granted a stock-based award to a new employee, Federico Grossi, UNITY’s Chief Medical Officer, covering options to purchase 150,000 shares of UNITY common stock. The stock-based award w

GlobeNewswire 22 days ago

UBX
-0.44%
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVR

GlobeNewswire 23 days ago

UBX
-0.44%
We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 24 days ago

UBX
-0.44%
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024. “As recently discussed on our Ophthalmology Day for investors and analysts, diabetic macular edema represents a large underserved market due to inadequate response to anti-VEGF standard of care, continued vision los

GlobeNewswire 2 months ago

UBX
-0.44%
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024

SAN FRANCISCO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that it will host an in-person and virtual event for investors and analysts on Tuesday, October 15, 2024, at 8:00 a.m. ET in New York, NY. The event will feature presentations from prominent ophthalmology key opinion leaders (KOLs) and company management. UNITY Biotechnology Ophthalmology D

GlobeNewswire 4 months ago

UBX
-0.44%
UNITY Biotechnology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following investor conferences. H.C. Wainwright 4th Annual Ophthalmology Virtual ConferencePresentation Date and Time: Thursday, August 15, 2024 at 7:00 a.m. ETLocation: V

GlobeNewswire 5 months ago

UBX
-0.44%
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know

UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 5 months ago

UBX
-0.44%
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024. “Having expanded and extended our ASPIRE study to 50 patients and 36 weeks, respectively, to better assess the efficacy and durability of UBX1325 compared to aflibercept, we have been laser-focused on enrollment and exe

GlobeNewswire 5 months ago

UBX
-0.44%
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company’s corporate and product strategies. “Alicia’s impressive experience in ophthalmology product planning, commercial strategy, and scaling cross-functional teams will b

GlobeNewswire 6 months ago

UBX
-0.44%
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 6 months ago

UBX
-0.44%
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy

UNITY Biotechnology (UBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 8 months ago

UBX
-0.44%
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team remains focused on the enrollment and execution of our Phase 2b ASPIRE study in diabetic macular edema, comparing UBX1325 (foselutoclax) against aflibercept," said Anirvan Ghosh, Ph.D., chief executive officer

GlobeNewswire 8 months ago

UBX
-0.44%
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington. ARVO 2024 Presentation Details: Title: Effect of Patient Baseline Characteristics

GlobeNewswire 9 months ago

UBX
-0.44%
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been extended from 24 to 36 weeks to assess potentially greater durability compared to aflibercept. In addition, the study is being upsized from 40 to 50 patients to increase the statistical power. The ASPIRE study is desig

GlobeNewswire 9 months ago

UBX
-0.44%
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2023. "On the heels of positive BEHOLD data, our team is currently single-mindedly focused on the enrollment and execution of our Phase 2b ASPIRE study in diabetic macular edema, comparing UBX1325 (foseluto

GlobeNewswire 9 months ago

UBX
-0.44%
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nature Medicine that supports the clearance of senescent cells in the retina as a therapeutic approach that can lead to long-term improvements in vision in patients with diabetic macular edema (DME). Sustained hyperglycemia fr

GlobeNewswire 11 months ago

UBX
-0.44%

Performance Overview

Return	UBX	S&P 500
YTD	+133.33%	+2.24%
1-Year	+31.76%	+23.48%
3-Year	-79.45%	+36.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Unity Biotechnology, Inc. (UBX)

UNITY Biotechnology Reports Granting of New Employment Inducement Award

UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024

UNITY Biotechnology to Participate in Upcoming Investor Conferences

UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting

UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

Performance Overview